신경학용 AI 시장 규모, 점유율 및 동향 분석 보고서 : 용도별, 신경질환별, 구성 요소별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

AI in Neurology Market Summary

The global AI in neurology market size was estimated at USD 760.0 million in 2025 and is projected to reach USD 4.5 billion by 2033, growing at a CAGR of 24.9% from 2026 to 2033. The rising global prevalence of neurological disorders, along with the increasing focus on early diagnosis and precision medicine, are among the key factors driving market expansion.

In addition, growing adoption of remote monitoring solutions, coupled with supportive government initiatives and evolving regulatory frameworks, further drives the integration of AI technologies into neurological care, enhancing diagnostic accuracy, improving patient outcomes, and streamlining clinical workflows.

The section below outlines the key factors driving market growth, highlighting the rising prevalence of neurological disorders, the need for early diagnosis, and support from government and regulatory bodies.

Global AI in Neurology Market Report Segmentation

This report forecasts revenue growth and provides, at global, regional, and country levels, an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global AI in neurology market report based on component, application, neurological condition, end use, and region:

• Component Outlook (Revenue, USD Million, 2021 - 2033)
• Software
• AI-enabled Devices
• Services
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Neuroimaging & Diagnostics
• Clinical Decision Support Systems (CDSS)
• Disease Progression Monitoring
• Brain-Computer Interface (BCI) & Neurotechnology
• Rehabilitation & Therapy Management
• Drug Discovery & Development
• Others
• Neurological Condition Outlook (Revenue, USD Million, 2021 - 2033)
• Stroke
• Alzheimer's Disease & Dementia
• Parkinson's Disease
• Epilepsy
• Multiple Sclerosis
• Traumatic Brain Injury (TBI)
• Brain Tumors
• Others
• End use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Clinics
• Neurology Centers
• Research & Academic Institutions
• Pharmaceutical & Biotechnology Companies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Component Segment
  • 1.2.2. Application Segment
  • 1.2.3. Neurological Condition Segment
  • 1.2.4. End Use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. AI in Neurology Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
  • 3.2.3. Market opportunity analysis
  • 3.2.4. Market challenges analysis
• 3.3. Case Study Insights
• 3.4. AI in Neurology Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.4.1.1. Supplier power
    • 3.4.1.2. Buyer power
    • 3.4.1.3. Substitution threat
    • 3.4.1.4. Threat of new entrant
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Technological landscape
    • 3.4.2.3. Economic landscape
    • 3.4.2.4. Environmental Landscape
    • 3.4.2.5. Legal Landscape
    • 3.4.2.6. Social Landscape

Chapter 4. AI in Neurology Market: Component Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global AI in Neurology Market Component Movement Analysis
• 4.3. Global AI in Neurology Market Size & Trend Analysis, by Component, 2021 - 2033 (USD Million)
• 4.4. Software
  • 4.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.5. AI-enabled Devices
  • 4.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.6. Services
  • 4.6.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. AI in Neurology Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global AI in Neurology Market Application Movement Analysis
• 5.3. Global AI in Neurology Market Size & Trend Analysis, by Application, 2021 - 2033 (USD Million)
• 5.4. Neuroimaging & Diagnostics
  • 5.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.5. Clinical Decision Support Systems (CDSS)
  • 5.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.6. Disease Progression Monitoring
  • 5.6.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.7. Drug Discovery & Development
  • 5.7.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.8. Brain-Computer Interface (BCI) & Neurotechnology
  • 5.8.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.9. Rehabilitation & Therapy Management
  • 5.9.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.10. Others
  • 5.10.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. AI in Neurology Market: Neurological Condition Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global AI in Neurology Market: Neurological Condition Movement Analysis
• 6.3. Global AI in Neurology Market Size & Trend Analysis, by Neurological Condition, 2021 - 2033 (USD Million)
• 6.4. Stroke
  • 6.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.5. Alzheimer's Disease & Dementia
  • 6.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.6. Parkinson's Disease
  • 6.6.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.7. Epilepsy
  • 6.7.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.8. Multiple Sclerosis
  • 6.8.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.9. Traumatic Brain Injury (TBI)
  • 6.9.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.10. Brain Tumors
  • 6.10.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.11. Others
  • 6.11.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. AI in Neurology Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global AI in Neurology Market: End Use Movement Analysis
• 7.3. Global AI in Neurology Market Size & Trend Analysis, by End Use, 2021 - 2033 (USD Million)
• 7.4. Hospitals & Clinics
  • 7.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.5. Neurology Centers
  • 7.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.6. Research & Academic Institutions
  • 7.6.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.7. Pharmaceutical & Biotechnology Companies
  • 7.7.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.8. Others
  • 7.8.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. AI in Neurology Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2025 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
• 8.4. North America
  • 8.4.1. U.S.
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. Canada
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Canada market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Mexico
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
• 8.5. Europe
  • 8.5.1. UK
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. UK market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. Germany
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Germany market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. France
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. France market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. Italy
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Italy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Spain
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. Spain market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Norway
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Norway market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. Sweden
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Regulatory framework
    • 8.5.7.3. Competitive scenario
    • 8.5.7.4. Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5.8. Denmark
    • 8.5.8.1. Key country dynamics
    • 8.5.8.2. Regulatory framework
    • 8.5.8.3. Competitive scenario
    • 8.5.8.4. Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Japan
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Japan market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. China
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. China market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. India
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. India market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.6.4. Australia
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Australia market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.6.5. South Korea
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.6.6. Thailand
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
• 8.7. Latin America
  • 8.7.1. Brazil
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. Argentina
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
• 8.8. MEA
  • 8.8.1. South Africa
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory framework
    • 8.8.1.3. Competitive scenario
    • 8.8.1.4. South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.8.2. Saudi Arabia
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.8.3. UAE
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Regulatory framework
    • 8.8.3.3. Competitive scenario
    • 8.8.3.4. UAE market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.8.4. Kuwait
    • 8.8.4.1. Key country dynamics
    • 8.8.4.2. Regulatory framework
    • 8.8.4.3. Competitive scenario
    • 8.8.4.4. Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2025
• 9.4. Company Profiles/Listing
  • 9.4.1. GE Healthcare
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Technology type benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Cortechs.ai
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Technology type benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Viz.ai
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Technology type benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. RapidAI (trademarks of iSchemaView, Inc)
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Technology type benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Aidoc
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Technology type benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Brainomix
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Technology type benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Avicenna.AI
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Technology type benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Natus
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Technology type benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Hyperfine
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Technology type benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. PERSYST DEVELOPMENT LLC
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Technology type benchmarking
    • 9.4.10.4. Strategic initiatives
  • 9.4.11. Ceribell, Inc.
    • 9.4.11.1. Company overview
    • 9.4.11.2. Financial performance
    • 9.4.11.3. Technology type benchmarking
    • 9.4.11.4. Strategic initiatives
  • 9.4.12. Empatica Inc.
    • 9.4.12.1. Company overview
    • 9.4.12.2. Financial performance
    • 9.4.12.3. Technology type benchmarking
    • 9.4.12.4. Strategic initiatives
  • 9.4.13. Koninklijke Philips N.V.
    • 9.4.13.1. Company overview
    • 9.4.13.2. Financial performance
    • 9.4.13.3. Technology type benchmarking
    • 9.4.13.4. Strategic initiatives
  • 9.4.14. Siemens Healthiness
    • 9.4.14.1. Company overview
    • 9.4.14.2. Financial performance
    • 9.4.14.3. Technology type benchmarking
    • 9.4.14.4. Strategic initiatives